#United States #Kuala Lumpur #INOVIO #DNA medicines #Hemophilia

INOVIO's Participation in the World Federation of Hemophilia Congress

INOVIO (NASDAQ: INO), the leading biotechnology firm dedicated to the advancement and commercialization of DNA medicines, has announced its active participation in the upcoming World Federation of Hemophilia Congress. This prestigious scientific event is scheduled to take place in Kuala Lumpur, Malaysia. The congress serves as a vital platform for scientists, healthcare professionals, and researchers to share and discuss the latest advancements in the field of bleeding disorders, particularly hemophilia.

Presentations Scheduled on April 22, 2026

The congress will feature two key presentations by INOVIO on April 22, 2026. The first presentation is titled “Next Gen Protein Replacement Therapeutics DNA-Encoded Protein (DPROT) Technology Demonstrates in vivo Production of Functional FVIII in Mouse Model.” This innovative approach focuses on the production of Factor VIII (FVIII) protein, vital for blood clotting, through an advanced DNA-encoded protein technology, showcasing promising results from animal models.

The second presentation, “FVIII Expression Via Non-viral Vector DNA Medicine Platform Results in Efficacious Levels of FVIII Protein and Correction of the Bleeding Phenotype in Hemophilia A Mice,” highlights INOVIO’s pioneering work in using non-viral vectors for gene delivery. The findings demonstrate significant advances in producing therapeutic levels of FVIII, which could potentially alter the treatment landscape for patients with Hemophilia A, offering hope for more effective treatments with fewer complications.

INOVIO’s Commitment to Innovative Solutions

INOVIO has consistently been at the forefront of biotechnology, focusing on developing solutions for diseases such as HPV-related conditions, various cancers, and infectious diseases. By leveraging its proprietary technologies, INOVIO aims to teach the body how to fight diseases through its unique DNA medicines, a concept that is increasingly gaining traction in the medical community.

The company plans to share all relevant abstracts from these presentations on its website following the event, allowing broader access to their groundbreaking research. The insights gained during this congress could highlight pathways for future studies and applications of DNA medicine, potentially benefitting countless patients globally.

Moreover, INOVIO's participation underlines the importance of collaborative efforts in the medical community aimed at improving patient care in areas of high unmet medical need. As the company shares its research findings with the larger scientific community, it not only contributes to ongoing discussions but also encourages the dialogue around sustainable solutions to global health challenges.

How to Follow INOVIO’s Progress

For those interested in a deeper dive into INOVIO's advancements in DNA medicines, updates will be available on their official website, www.inovio.com. Stakeholders, media professionals, and the public are encouraged to visit the site for further information and resources.

As INOVIO steps forward into 2026, its vision to transform the landscape of medicine through innovative DNA techniques stands as a testament to its commitment to healing and health advancement. Keep an eye on this trailblazer in biotechnology, as its future endeavors may hold significant implications for treating complex health issues, including hemophilia and beyond.